Get to know our clinical trials

Unblinded clinical trial of ELA026 in participants with LHHs.

Imagen de la Dra. Sara Villar, especialista en Hematología y Hemoterapia de la Clínica Universidad de Navarra.
Dr. Sara Villar Fernández
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • PHASE II/III, MULTICENTER, UNBLINDED, SINGLE-BLINDED, SINGLE-ARM, LANDMARK COMPARATIVE STUDY TO EVALUATE ELA026 IN PARTICIPANTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLS).
  • Code EudraCT: 2025-520624-25-00
  • Protocol number: ELA026-CP002
  • Promoter: Electra Therapeutics
  • Molecule/Drug: ELA026
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Read more about this clinical trial
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION